moxifloxacin has been researched along with propranolol in 13 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (propranolol) | Trials (propranolol) | Recent Studies (post-2010) (propranolol) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 33,310 | 3,406 | 3,218 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Ward, KW | 1 |
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bhadresa, S; Coon, DJ; Lawrence, MS; Magiera, D; Struharik, M; Ward, KW | 1 |
| Bando, K; Deguchi, J; Honda, Y; Watanabe, H; Yamada, T | 1 |
1 review(s) available for moxifloxacin and propranolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for moxifloxacin and propranolol
| Article | Year |
|---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
New drugs and dosage forms.
Topics: Adrenergic beta-Antagonists; alpha-Galactosidase; Aza Compounds; Dosage Forms; Fluoroquinolones; Humans; Isoenzymes; Moxifloxacin; Ophthalmic Solutions; Pharmaceutical Preparations; Propranolol; Quinolines | 2003 |
Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions.
Topics: Animals; Aza Compounds; Chlorocebus aethiops; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Evaluation, Preclinical; Erythromycin; Fluoroquinolones; Lidocaine; Mass Spectrometry; Models, Animal; Moxifloxacin; Pharmacokinetics; Phenytoin; Prednisolone; Propranolol; Quinolines; Species Specificity | 2009 |
Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes.
Topics: Arrhythmias, Cardiac; Astemizole; Calcium; Calcium Channel Blockers; Cardiotonic Agents; Cell Differentiation; Cells, Cultured; Digoxin; Dose-Response Relationship, Drug; Drug Discovery; Fluoroquinolones; Induced Pluripotent Stem Cells; Isoproterenol; Moxifloxacin; Myocardial Contraction; Myocytes, Cardiac; Propranolol; Toxicity Tests; Verapamil | 2017 |